0 30/11/2023 2023-11-30 false false false false false false false false false false true false false true false false false false false false false No description of principal activities is disclosed 2022-12-01 Sage Accounts Production 21.0 - FRS102_2021 xbrli:pure xbrli:shares iso4217:GBP SC645985 2022-12-01 2023-11-30 SC645985 2023-11-30 SC645985 2022-11-30 SC645985 bus:RegisteredOffice 2022-12-01 2023-11-30 SC645985 bus:LeadAgentIfApplicable 2022-12-01 2023-11-30 SC645985 bus:Director1 2022-12-01 2023-11-30 SC645985 core:WithinOneYear 2023-11-30 SC645985 core:WithinOneYear 2022-11-30 SC645985 bus:Director1 2022-11-30 SC645985 bus:Director1 2023-11-30 SC645985 bus:Director1 2022-11-30 SC645985 bus:Director1 2021-12-01 2022-11-30 SC645985 bus:Micro-entities 2022-12-01 2023-11-30 SC645985 bus:AuditExemptWithAccountantsReport 2022-12-01 2023-11-30 SC645985 bus:FullAccounts 2022-12-01 2023-11-30 SC645985 bus:SmallCompaniesRegimeForAccounts 2022-12-01 2023-11-30 SC645985 bus:PrivateLimitedCompanyLtd 2022-12-01 2023-11-30
Company registration number: SC645985
Bonaccord Life Sciences Limited
Unaudited filleted financial statements
30 November 2023
Bonaccord Life Sciences Limited
Contents
Directors and other information
Accountants report
Statement of financial position and notes to the financial statements
Bonaccord Life Sciences Limited
Directors and other information
Director Patricia Barclay
Company number SC645985
Registered office 31 Merchiston Park
Edinburgh
EH10 4PW
Business address 31 Merchiston Park
Edinburgh
EH10 4PW
Accountants Paterson Boyd & Co
Chartered Certified Accountants
18 North Street
Glenrothes
Fife
KY7 5NA
Bonaccord Life Sciences Limited
Report to the director on the preparation of the
unaudited statutory financial statements of Bonaccord Life Sciences Limited
Year ended 30 November 2023
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Bonaccord Life Sciences Limited for the year ended 30 November 2023 which comprise the statement of financial position and related notes from the company's accounting records and from information and explanations you have given us.
As a practising member firm of ICAS , we are subject to its ethical and other professional requirements which are detailed at http://www.icas.com/accountspreparationguidance.
This report is made solely to the director of Bonaccord Life Sciences Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Bonaccord Life Sciences Limited and state those matters that we have agreed to state to them, as a body, in this report in accordance with the requirements of ICAS as detailed at http://www.icas.com/accountspreparationguidance. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Bonaccord Life Sciences Limited and its director as a body for our work or for this report.
It is your duty to ensure that Bonaccord Life Sciences Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Bonaccord Life Sciences Limited. You consider that Bonaccord Life Sciences Limited is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the financial statements of Bonaccord Life Sciences Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.
Paterson Boyd & Co
Chartered Certified Accountants
18 North Street
Glenrothes
Fife
KY7 5NA
29 August 2024
Bonaccord Life Sciences Limited
Statement of financial position
30 November 2023
2023 2022
£ £ £ £
Current assets 1,615 2,840
Prepayments and accrued income 280 -
_______ _______
1,895 2,840
Creditors: amounts falling due within one year ( 2,869) ( 2,164)
_______ _______
Net current (liabilities)/assets ( 974) 676
_______ _______
Total assets less current liabilities ( 974) 676
Accruals and deferred income ( 558) ( 500)
_______ _______
Net (liabilities)/assets ( 1,532) 176
_______ _______
Capital and reserves ( 1,532) 176
_______ _______
Notes to the financial statements
Bonaccord Life Sciences Limited
Year ended 30 November 2023
During the year the director entered into the following advances and credits with the company:
2023
Balance brought forward Advances /(credits) to the director Amounts repaid Balance o/standing
£ £ £ £
Patricia Barclay 465 1,500 ( 3,110) ( 1,145)
_______ _______ _______ _______
2022
Balance brought forward Advances /(credits) to the director Amounts repaid Balance o/standing
£ £ £ £
Patricia Barclay - 11,161 ( 10,696) 465
_______ _______ _______ _______
For the year ending 30 November 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors responsibilities:
- The member has not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
- The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
The financial statements have been prepared in accordance with the micro-entity provisions and have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.
These financial statements were approved by the board of directors and authorised for issue on 29 August 2024 , and are signed on behalf of the board by:
Patricia Barclay
Director
Company registration number: SC645985
The company is a private company limited by shares, registered in Scotland.